Mouse leukemia: therapy with monoclonal antibodies against a thymus differentiation antigen.
Monoclonal antibodies against a thymus cell differentiation antigen (Thy-1.1) were effective in the therapy of a transplanted mouse leukemia. Passive immunization resulted in high titers of cytotoxic antibody in the serum of treated mice and the suppression of metastatic tumor cells. The tumor-suppressive effects of the monoclonal antibodies were amplified by the administration of exogenous complement. This combined antibody and complement therapy resulted in the cure of leukemia in a significant proportion of the treated animals.
D000818:Animals; D000918:Antibody Specificity; D000954:Antigens, Surface; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D002454:Cell Differentiation; D002999:Clone Cells / Q000276:immunology; D003602:Cytotoxicity, Immunologic; D007167:Immunotherapy; D007942:Leukemia, Experimental / Q000601:surgery / Q000628:therapy*; D051379:Mice; D008815:Mice, Inbred Strains; D009362:Neoplasm Metastasis; D013601:T-Lymphocytes / Q000276:immunology*
D000954:Antigens, Surface; D000961:Antilymphocyte Serum